Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTOR registry of radium-223 outcomes in symptomatic metastatic castration-resistant prostate cancer
NL-OMON55579Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa) and bone metastases, sponsored by Netherlands Cancer Institute. Primary endpoint: Symptomatic Skeletal Event. Started Dec 2015; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on NL-OMON55579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55579.